RBC Capital Maintains Outperform on Viracta Therapeutics, Lowers Price Target to $4
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Gregory Renza maintains an Outperform rating on Viracta Therapeutics (NASDAQ:VIRX) but lowers the price target from $6 to $4.
August 15, 2024 | 2:56 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
RBC Capital analyst Gregory Renza maintains an Outperform rating on Viracta Therapeutics but lowers the price target from $6 to $4.
The Outperform rating suggests positive sentiment, but the lowered price target indicates tempered expectations. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100